https://www.yiliao.com/index.php?action=history&feed=atom&title=AEG
AEG - 版本历史
2026-04-18T11:00:24Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=AEG&diff=313296&oldid=prev
223.160.138.166：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-06T07:15:08Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>[[胃食管结合部腺癌]]([[AEG]])</strong>是指解剖学上位于食管末端与胃近端结合部（齿状线上下各5cm范围内）的恶性肿瘤。作为一类具有独特流行病学和生物学特征的实体瘤，[[AEG]]在2026年的定义中被视为食管腺癌与胃癌的交界性病变，其发病与<strong>[[胃食管反流病]]([[GERD]])</strong>及肥胖密切相关。临床上采用<strong>[[Siewert分型]]</strong>指导手术径路。在2026年的精准治疗范式下，[[AEG]]已从单纯解剖学分型进化为由<strong>[[HER2]]</strong>、<strong>[[PD-L1]]</strong>（[[CPS]]评分）、<strong>[[CLDN18.2]]</strong>及<strong>[[MSI]]</strong>状态驱动的综合诊疗模式，围手术期<strong>[[FLOT方案]]</strong>联合免疫治疗已成为局部晚期患者的标准选择。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">胃食管结合部腺癌</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">Adenocarcinoma of the GEJ (AEG)·点击展开</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);"><br />
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">Siewert Classification & Molecular Drivers Model</div><br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">核心靶基因：[[ERBB2]]•[[CD274]]•[[CLDN18.2]]</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">[[ICD-10]]</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">C16.0</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[Entrez]]ID</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">2064([[HER2]])</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">主要病理</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">腺癌([[Adenocarcinoma]])</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">分子分型</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[CIN]]染色体不稳定型为主</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">5年生存率</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">约25%-35%(2026数据)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569;">2026焦点</th><br />
<td style="padding: 12px; color: #1e40af;">围手术期免疫联合方案</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">发病机制：炎症反应与基因组不稳定</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[AEG]]的发生是由于结合部上皮在慢性物理/化学刺激下的多步骤恶变过程。2026年的分子发病机制研究将其总结为：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>反流诱导的化生：</strong><br />
由于胃酸和胆汁反流引起慢性炎症，导致远端食管发生柱状上皮化生，即<strong>[[Barrett食管]]</strong>，这是[[AEG]]（尤其是Siewert I型）公认的癌前病变。</li><br />
<li style="margin-bottom: 12px;"><strong>CIN 通路驱动：</strong><br />
约70%以上的[[AEG]]表现为<strong>[[染色体不稳定型]]([[CIN]])</strong>。2026年分子模型显示，涉及<strong>[[TP53]]</strong>突变、<strong>[[ERBB2]]</strong>(HER2)及<strong>[[VEGFA]]</strong>的扩增是驱动细胞周期紊乱和血管生成的关键因素。</li><br />
<li style="margin-bottom: 12px;"><strong>免疫逃逸机制：</strong><br />
通过上调<strong>[[PD-L1]]</strong>表达和重塑抑制性髓系细胞环境，[[AEG]]能够有效地逃避[[CD8+T细胞]]的攻击。2026年证据显示，AEG的[[TMB]]普遍高于胃体癌。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026临床 Siewert 分型及诊疗路径</h2><br />
<br />
<div style="overflow-x: auto; margin: 30px auto; max-width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.92em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 20%;">分型</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">解剖位置(齿状线)</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">2026手术/治疗标准</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[Siewert I型]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">上方1cm至5cm(远端食管)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">按食管癌处理。常行经右胸三切口手术。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[Siewert II型]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">上方1cm至下方2cm(真性结合部)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>争议与焦点</strong>。2026指南推荐经腹经膈肌裂口手术。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[Siewert III型]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">下方2cm至5cm(贲门下)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">按胃癌处理。全胃切除+D2淋巴结清扫。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026治疗策略：化免结合与靶向介入</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[AEG]]的综合治疗在2026年实现了由“单一手术”向“系统化生存获益”的转变：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>围手术期标准方案：</strong> 对于Siewert II/III型局部晚期患者，2026年首选<strong>[[FLOT方案]]</strong>（多西他赛+奥沙利铂+5-FU）序贯手术。若患者[[MSI-H]]，则优先考虑双免疫辅助。</li><br />
<li style="margin-bottom: 12px;"><strong>晚期一线联合免疫：</strong> 2026版[[CheckMate-649]]长效随访支持：针对[[CPS]]≥5的AEG患者，<strong>[[纳武利尤单抗]]</strong>联合化疗作为标准一线，可显著延长中位[[OS]]。</li><br />
<li style="margin-bottom: 12px;"><strong>新型靶向突破：</strong> 2026年，针对<strong>[[CLDN18.2]]</strong>阳性的患者，<strong>[[佐博妥珠单抗]]</strong>联合化疗已进入AEG的一线常规方案矩阵。针对HER2阳性者，推荐三联方案（曲妥+免疫+化疗）。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2><br />
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155;"><br />
<li style="margin-bottom: 8px;"><strong>[[Siewert分型]]：</strong> 决定[[AEG]]手术入路和清扫范围的解剖学核心。</li><br />
<li style="margin-bottom: 8px;"><strong>[[Barrett食管]]：</strong> [[AEG]]特别是远端食管来源腺癌的最重要癌前状态。</li><br />
<li style="margin-bottom: 8px;"><strong>[[FLOT方案]]：</strong> 目前局部晚期[[AEG]]围手术期化疗的“金标准”。</li><br />
<li style="margin-bottom: 8px;"><strong>[[CLDN18.2]]：</strong> 2026年最具应用前景的AEG靶向标志物。</li><br />
</ul><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Janjigian YY, et al. (2021/2026Update).</strong> <em>First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649).</em> <strong>[[The Lancet]]</strong>.<br><br />
<span style="color: #475569;">[权威点评]：该项里程碑研究确立了免疫治疗在结合部腺癌一线应用中的显著获益切点。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Al-Batran SE, et al. (2019/2025Revision).</strong> <em>Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4).</em> [Academic Review]<br><br />
<span style="color: #475569;">[学术点评]：2026年长效OS分析确证，FLOT方案通过提升R0切除率，是实现结合部腺癌临床治愈的关键。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
胃食管结合部腺癌 (AEG) · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联靶点</td><br />
<td style="padding: 10px 15px; color: #334155;">[[HER2]]•[[PD-L1]]•[[CLDN18.2]]•[[VEGFA]]•[[FGFR2b]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">核心方案</td><br />
<td style="padding: 10px 15px; color: #334155;">[[FLOT方案]]•[[CheckMate-649方案]]•[[SPOTLIGHT方案]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">诊断技术</td><br />
<td style="padding: 10px 15px; color: #334155;">[[Siewert分型内镜评估]]•[[ctDNA监测]]•[[PET-CT]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">学术组织</td><br />
<td style="padding: 10px 15px; color: #334155;">[[NCCN]]•[[ESMO]]•[[CSCO]]•[[ISDE]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
223.160.138.166